In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
Plant-based artificial Christmas trees set to launch this December
In California, artificial Christmas tree maker Balsam Brands will launch a new line of trees for 2025’s holiday season that use needles made of...
Artist Sam Shoemaker takes mushroom kayak on twelve-hour journey
In California, an artist and “mycologist” has crossed 26 miles of ocean in a kayak made of mycelium, the root system of mushrooms.
Sam...
Canadian funeral group becomes first to offer Loop’s mycelium coffins and urns
In Canada, Mount Pleasant Group’s Meadowvale Cemetery, Funeral and Cremation Centres have become the first in Canada to offer the Loop Living Cocoon and...